Amongst the well-documented BC subtypes, HER2-positive and triple-negative (defined by the absence of ER, PR, HER2/ERBB2 expression) breast tumors present distinct challenges in diagnosis and therapeutic needs. The gene discussed is ERBB2; the disease is breast cancer.